Compare Adaptive Biotechnologies Corp (ADPT) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Carlyle Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Carlyle Group Inc trades at $48.27 (market cap $17.23B). The key difference: Carlyle Group Inc is far larger — about 4.3× Adaptive Biotechnologies Corp's market cap, and Carlyle Group Inc pays a 2.9% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CG | |
|---|---|---|
Market Cap | $4.04B | $17.23B |
Sector | Health | Financials |
52-Week High | $25.45 | $69.35 |
52-Week Low | $12.30 | $40.52 |
Enterprise Value | $4.10B | — |
Dividend Yield | — | 2.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
